Mobocertinib and Colchicine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mobocertinib
Colchicine
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You've been prescribed mobocertinib (Exkivity) for cancer and colchicine for gout or inflammation. Your body breaks colchicine down using a liver system called CYP3A. Mobocertinib can speed up that system, so your body may clear colchicine faster than usual. That could leave too little colchicine in your blood to do its job, meaning your gout symptoms might not be controlled as well.
The good news is this is based on theory, not strong real-world reports, and your care team can plan for it. Please don't change or stop either medicine on your own. Just let your pharmacist or doctor know you take both so they can watch how you're doing and adjust things if needed.
Effect: Mobocertinib may induce CYP3A-mediated metabolism of colchicine, potentially lowering colchicine plasma concentrations and reducing efficacy (therapeutic failure).
- Mechanism: CYP3A induction of the substrate (colchicine); neither drug is a prodrug requiring activation.
- Direction: Reduced colchicine exposure (AUC/Cmax). For reference, mobocertinib reduced midazolam AUC by ~16-32%.
- Evidence: Theoretical; severity major; onset unspecified.
- Management: Avoid combining with narrow-margin CYP3A substrates. If unavoidable, colchicine dose may be increased per guidance and clinical response monitored (e.g., symptom control).
What happens
Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure
Interaction Deep Dive
Because mobocertinib acts as a CYP3A inhibitor, its combined use with a CYP3A substrate that has a narrow therapeutic index should be avoided, since the resulting reduction in substrate plasma levels can produce serious therapeutic failures even when concentration changes are small. When mobocertinib was given together with midazolam (a CYP3A substrate), the midazolam AUC fell by 32% and 16%, respectively1.
Why it happens (mechanism)
Induction of the metabolism of CYP3A substrates by mobocertinib
How to manage this interaction
Your care team can manage this safely. Keep taking both medicines exactly as prescribed unless your doctor or pharmacist tells you otherwise.
- Tell your prescriber and pharmacist that you take mobocertinib and colchicine together.
- Because mobocertinib may lower colchicine levels, your colchicine dose may be adjusted and individualized by your team, and they may watch your response more closely.
- Report if your gout or inflammation symptoms are not improving or seem to return, since that could signal reduced effect.
- Your team may also consider whether an alternative is appropriate.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) When mobocertinib 160 mg once daily was given together with midazolam (a CYP3A substrate) administered orally or intravenously, the AUC of midazolam was reduced by 32% and 16%, respectively1.
Common questions
Can I take Mobocertinib and Colchicine together?
Mobocertinib may speed up how your body clears colchicine, which could make colchicine work less well. Don't change anything yourself, but tell your pharmacist or doctor so they can adjust your dose and monitor your symptoms. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Mobocertinib and Colchicine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Mobocertinib and Colchicine interaction managed?
Your care team can manage this safely. Keep taking both medicines exactly as prescribed unless your doctor or pharmacist tells you otherwise. Tell your prescriber and pharmacist that you take mobocertinib and colchicine together. Because mobocertinib may lower colchicine levels, your colchicine dose may be adjusted and individualized by your team, and they may watch your response more closely. Rep… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Mobocertinib or Colchicine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: EXKIVITY(TM) oral capsules, mobocertinib oral capsules. Takeda Pharmaceuticals America Inc (per FDA), Lexington, MA, 2021.
Keep reading about Mobocertinib
Keep reading about Colchicine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist